CD8A and cancer: For therapeutic translation, this study suggests a cancer therapy strategy through a combined treatment approach of "spatial blockade + signaling inhibition." Specifically, the PD-1 antibody targets the PD-1 receptor on CD8+ T cells, blocking the immunosuppressive signal mediated by the PD-1/PD-L1 interaction and thereby reversing T-cell exhaustion.